Shanghai Henlius Biotech Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Henlius Biotech Co. Ltd.
Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.
After years of laying the foundations, China Biotech Inc. is being pursued by multinationals looking for innovative candidates to commercialize in both China and globally, executives and deals from the just concluded J.P Morgan Global Healthcare Conference show.
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
- Large Molecule
- Other Names / Subsidiaries
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.